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Abstract
Glucagon-like peptide-1 (GLP-1, GLP-17–36amide) and its sister peptide gluca-
gon-like peptide 2 (GLP-2) influence numerous intestinal functions and GLP-
2 greatly increases intestinal blood flow. We hypothesized that GLP-1 also
stimulates intestinal blood flow and that this would impact on the overall
digestive and cardiovascular effects of the hormone. To investigate the influ-
ence of GLP-1 receptor agonism on mesenteric and renal blood flow and car-
diovascular parameters, we carried out a double-blinded randomized clinical
trial. A total of eight healthy volunteers received high physiological subcuta-
neous injections of GLP-1, GLP-19–36 amide (bioactive metabolite), exenatide
(stable GLP-1 agonist), or saline on four separate days. Blood flow in mesen-
teric, celiac, and renal arteries was measured by Doppler ultrasound. Blood
pressure, heart rate, cardiac output, and stroke volume were measured contin-
uously using an integrated system. Plasma was analyzed for glucose, GLP-1
(intact and total), exenatide and Pancreatic polypeptide (PP), and serum for
insulin and C-peptide. Neither GLP-1, GLP-19–36 amide, exenatide nor saline
elicited any changes in blood flow parameters in the mesenteric or renal arter-
ies. GLP-1 significantly increased heart rate (two-way ANOVA, injection
[P = 0.0162], time [P = 0.0038], and injection 9 time [P = 0.082]; Tukey
post hoc GLP-1 vs. saline and GLP-19–36amide [P < 0.011]), and tended to
increase cardiac output and decrease stroke volume compared to GLP-19–36
amide and saline. Blood pressures were not affected. As expected, glucose levels
fell and insulin secretion increased after infusion of both GLP-1 and exe-
natide.
Introduction
The hormone glucagon-like peptide-1 (GLP-1,
GLP-17–36amide) is best known for its actions on the
endocrine pancreas, where it potentiates glucose-induced
insulin secretion via activation of specific GLP-1 receptors
and inhibits glucagon secretion (Holst 2007). These
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actions led to the development of GLP-1 receptor agonists
(GLP-1-RAs), which are now being used worldwide for
the treatment of type 2 diabetes (Holst et al. 2008). But
GLP-1 has other activities, which are important both
physiologically and therapeutically. Thus, it inhibits appe-
tite, and thereby food intake (Flint et al. 1998), which is
expedient considering the association between obesity and
type 2 diabetes, and a GLP-1 receptor agonist has recently
been approved for the therapy of obesity (Pi-Sunyer et al.
2015). Cardiovascular actions of GLP-1 and the GLP-1
RA have also attracted considerable attention (Sivertsen
et al. 2012) because the agonists: (1) may improve
myocardial performance; (2) may reduce myocardial
damage after ischemia; (3) may improve endothelial dys-
function in diabetes; and (4) clearly improve cardiovas-
cular risk factors, including improved blood pressure,
lowered body weight, improved blood lipids, and benefi-
cial changes in high-sensitivity C-reactive protein
(hsCRP), plasminogen activator inhibitor-1 (PAI-1), and
(pro)brain natriuretic peptide ((pro)BNP) (Tate et al.
2015). The mechanisms behind these actions are unclear;
some may be related to the general metabolic improve-
ment obtained during GLP-1 therapy (weight loss,
improved glycemic control); others may be related to
interaction with GLP-1 receptors in the involved organs
systems (Sivertsen et al. 2012). The mapping of the
GLP-1 receptor localization has been hampered by prob-
lems with inadequate specificity of the antibodies
employed (Pyke and Knudsen 2013; Pyke et al. 2014;
Ussher and Drucker 2014). This is particularly relevant
for the cardiovascular system, where a less dense expres-
sion of the receptors, compared to the pancreatic islets,
makes localization studies more difficult. Recently, the
GLP-1 receptor has been localized to the renal vascula-
ture (Jensen et al. 2015). Moreover, it has been sug-
gested that there may be expression of GLP-1 receptors
in the gastrointestinal system (Pyke et al. 2014), where
GLP-1 has motor functions (Holst 2007) and may pro-
mote mucosal growth (Simonsen et al. 2007). These
actions are reminiscent of those of the sister peptide,
glucagon-like peptide-2, produced and secreted in paral-
lel with GLP-1 from the intestinal L-cells (Buhl et al.
1988; Hartmann et al. 2000a). Perhaps associated with
its growth effects and metabolic actions on the gastroin-
testinal tract (Bremholm et al. 2011), GLP-2 markedly
stimulates intestinal blood flow in both experimental
animals and humans (Bremholm et al. 2009).
We therefore hypothesized that GLP-1 might have
similar actions on mesenteric blood flow in humans.
Indeed, GLP-1 has been demonstrated to dilate precon-
tracted mesenteric arteries (Ban et al. 2008) and to lower
vascular resistance in the perfused small intestine
in vitro (Hansen and Holst 2002). In vivo, GLP-1 is
metabolized rapidly by the enzyme, dipeptidyl peptidase-
4 (DPP-4), leading to the formation of a truncated
form, GLP-19–36amide (Deacon et al. 1995), which is inac-
tive with respect to insulin secretion, but seems to share
at least some of its vascular actions with intact GLP-1
(Ban et al. 2008). For the current studies, we, therefore,
also included experiments with the metabolite (and
competitive antagonist (Knudsen and Pridal 1996), GLP-
19–36 amide, and with a GLP-1-RA, exenatide, which is
widely used clinically because of its stability towards
DPP-4 (Klonoff et al. 2008). In this way, we could study
effects of the intact hormone as well as its metabolite
and a stabilized form, which does not give rise to for-
mation of the antagonist.
It was decided to use subcutaneous (s.c.) injections of
rather large doses of all three peptides because this was
known to produce a delayed plasma profile temporally
reminiscent of meal-related increases but at augmented
levels similar to those observed after, for instance, gastric
bypass operations (Vilsbøll et al. 2000; Jacobsen et al.
2012).
Materials and Methods
Participants
A total of eight young healthy volunteers (three females),
age 24.3 (2.7) [mean (SD)] years, height 176 (10) cm,
weight 71 (13) kg, BMI 22.6 (2.1) kg/m2 were included.
All had been screened by clinical examination and routine
blood biochemistry. All participants gave oral and written
consent to take part in the study. The Regional Commit-
tee on Biomedical Research Ethics (SJ-339) approved the
study protocol, and the trial was carried out in accor-
dance with the Helsinki II declaration and the regulations
of the Danish Data Protection Agency. The trial was reg-
istered at www.clinicaltrials.gov, Protocol Registration
number NCT01988545.
All of the volunteers received s.c. (lower abdomen)
GLP-1, GLP-19–36 amide, exenatide (Byetta), or isotonic
saline (placebo) on four separate trial days, in a double
blinded randomized design.
Test substances
Synthetic human GLP-1 (99% pure, purchased from
Bachem, Bubendorf, Germany) and synthetic human
GLP-19–36 amide (96% pure, purchased from Bachem,
Bubendorf, Germany) were dissolved in saline with 2%
albumin (CSL Behring GmbH, Marburg, Germany), sterile
filtered, dispensed into glass ampoules, and tested for
sterility and pyrogenes. Purity and structure were ascer-
tained by sequence, high-performance liquid
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chromatography, and mass analysis. Exenatide (ByettaR)
and isotonic saline were purchased commercially and used
directly.
Doppler ultrasound scanning
All examinations were performed by the same sonogra-
pher (UBA). The Doppler ultrasound equipment was a
Vivid E9 (GE Healthcare systems), equipped with a
2.5–4.0 MHz curvilinear transducer. The superior
mesenteric artery (SMA), celiac trunk (TC), and renal
artery (RA) were examined with participants lying in
the supine position and instructed not to move during
the trial session.
For each measurement, calculations based on the Dop-
pler spectra were made during five consecutive heartbeats
using the auto measure software. All Doppler parameters
(time averaged mean velocity [TAMV], diastolic velocity
[Vdia], and systolic velocity [Vsys]) were calculated by
algorithms incorporated in the software of the US appara-
tus, thus avoiding measurement bias.
Doppler-US parameters were measured at time 15, 0,
5, 15, 30, 45, 60, 90, and 120 min. The SMA and the TC
were examined by a longitudinal epigastric view, and
measurements were made as close to the ostia as possible.
The right RA was examined by a transverse epigastric
view, and measurements were made in the proximal
down sloping part of the artery; angle correction was used
as necessary. For each time point, we made three mea-
surements in the SMA, TC, and RA.
The volunteers, the laboratory technicians, and the
sonographer were all blinded to the sequence of test com-
pounds.
Calculations
The resistive index (RI) can be used to estimate the resis-
tance in a vessel. In this setup, a falling RI was taken to
indicate that the flow was increasing. The RI was calcu-
lated as RI = 1 – (Vdia/Vsys) where Vdia is the maximal
diastolic velocity and Vsys is the maximal systolic velocity.
Changes in the TAMV more directly reflect changes of
the flow in a vessel.
Cardiovascular measurements:
Cardiac parameters were continuously measured from
time 15 to 120 min. The task force monitor (TFM; CN
Systems, Graz, Austria) continuously measures the heart
rate, blood pressure (by finger plethysmography), cardiac
output (by impedance cardiography), and calculates
stroke volume (SV). The continuous, beat-to-beat mea-
suring of blood pressure was supplemented with the
conventional noninvasive oscillometric blood pressure
measurement. All data were stored from time 15 min to
120 min. We used data from the following periods
matched with the time measuring points: 0 min: 1–
0 min; 5 min: 0–5 min; 15 min: 6–15 min; 25 min: 16–
25 min; 35 min: 26–35 min; 45 min: 36–45 min; 60 min:
46–60 min; 75 min: 61–75 min; 90 min: 76–90 min; and
120 min: 91–120 min. This was done to eliminate brief
or short-lasting changes in cardiac parameters due to
accidental movement of the volunteer or slight distur-
bance during scanning.
Analyses
GLP-1 (total (i.e., GLP-17–36amide + GLP–19–36amide) and
intact), exendin-4, and pancreatic polypeptide (PP)
plasma concentrations were measured by radioimmunoas-
say after ethanol extraction as previously described (Ors-
kov et al. 1994; Kielgast et al. 2011; Dirksen et al. 2013;
Wewer Albrechtsen et al. 2015).
Plasma glucose was measured by the glucose oxidase
method using a glucose analyzer (Yellow Springs Instru-
ment, YSI Inc., Yellow Springs, OH).
Plasma insulin and C-peptide levels were measured on
a Cobas 8000, e602 module (Roche Diagnostics GmbH,
Mannheim) using, respectively, Cobas Insulin reagents
and Cobas Insulin Calibrator, and Cobas C-Peptide
reagents and Cobas C-Peptide Calibrator. The Cobas
module employs a sandwich electro-chemiluminescense
immunoassay (ECLIA).
Procedure
The experiments were carried out over 4 days under iden-
tical circumstances. The participants arrived after an over-
night fast, height and weight were measured, and a urine
human chorionic gonadotropin (HCG) test was per-
formed on the female volunteers (all tests were negative).
Intravenous access was then established. The task force
monitor equipment was attached following which the par-
ticipants rested for 15–20 min in the supine position.
Baseline measurements were made twice during the rest-
ing period. The following s.c. injections were given in
random order on the four experimental days: isotonic sal-
ine (1 mL); 10 lg exenatide (1 mL); 1.5 nmol/kg syn-
thetic GLP-19–36 amide (1 mL); and 1.5 nmol/kg synthetic
GLP-1 (1 mL).
Venous blood samples were collected into chilled
EDTA tubes containing, in final concentrations: valine
pyrrolidide (a DPP-4 inhibitor; 0.01 mmol/L; a gift from
Novo Nordisk A/S), and aprotinin (a protease inhibitor;
500 Kallikrein inhibitory unit (KIU)/mL, Trasylol; Bayer,
Marburg, Germany) at times 15, 0, 15, 30, 45, 60, 90,
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and 120 min and centrifuged at 1200g for 10 min at 4°C.
Plasma was then distributed into ice-chilled tubes (Min-
isorb, Nunc, Roskilde, Denmark) and stored at 20°C
pending analyses. Serum was stored in cryotubes and
stored at 80°C.
Statistical analysis
Blood flow and cardiac parameters as well as peptide and
glucose levels were compared on all days. Data was
assessed for normality using the D’Agostino & Pearson
omnibus normality test. All data except insulin and
c-peptide followed a normal distribution.
Analyses of normally distributed data were conducted
by two-way ANOVA followed by Tukey post hoc testing
if the ANOVA indicated significant differences between
the study days. As insulin and C-peptide data did not fol-
low a normal distribution, we calculated instead the
incremental areas under the curve (iAUCs) and compared
these using a one-way ANOVA with a post hoc test
(Tukey) if the ANOVA yielded significant differences.
Participant characteristics are expressed as means and
standard deviations (SD), while experimental data are
expressed as means and standard error of the mean
(SEM). Differences resulting in two-sided P < 0.05 were
considered significant. Statistical analyses were carried out
using Graphpad Prism version 6.00 for Mac, GraphPad
Software, La Jolla California USA.
Results
Side effects
None of the participants noted any discomfort over the
course of the experimental days.
GLP-1 and exenatide
Plasma concentrations of the test substances are shown in
Figure 1. Exenatide levels (Fig. 1A) rose slowly to an
apparent plateau around 300 pmol/L at 45 min and did
not fall during the observation time. On the GLP-1 infu-
sion day, total plasma GLP-1 concentrations (Fig. 1B)
rose within 15 min to a mean value around 300 pmol/L
and declined slowly thereafter, but were still elevated at
120 min. The levels of intact GLP-1 increased to approxi-
mately 50 pmol/L at 15 min and reached basal levels
around 90 min. The concentrations of the metabolite
GLP-19–36amide (Fig. 1C) rose to about 290 pmol/L at
30 min and declined slowly reaching near basal levels at
120 min.
Figure 1. Exendin-4, GLP-1, and GLP-19–36amide. (A) Exendin-4
levels (squares) on the exenatide day. (B) Total (filled triangles) and
intact (open triangles) GLP-1 levels on the GLP-1 day. (C) Total GLP-
1 levels (inverted triangles) on the GLP-19–36amide day. Data are
means (SEM).
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Metabolic effects
Plasma glucose (Fig. 2A) levels decreased following GLP-
1 injection from around 5 mmol/L to a nadir of
3.5 mmol/L occurring at 30 min, but returning to basal
levels at 90 min. Exenatide also lowered plasma glucose,
but less so than GLP-1 and with a more protracted pat-
tern with a nadir at 60 min. Neither saline nor the
metabolite, GLP-19–36amide influenced plasma glucose
levels.
Insulin (Fig. 2C–D) and C-peptide (Fig. 2E–F) gener-
ally varied in parallel, but with C-peptide levels being
slightly delayed compared to insulin. GLP-1 caused a rise
in insulin, peaking at 15 min and returning to basal levels
at 30 min, while C-peptide levels remained elevated until
60 min. Exenatide also caused a rise in insulin and C-
peptide levels, to about one-third of that caused by GLP-
1, but peaking around 30 min and thereafter rapidly
declining. There were no significant changes in response
to GLP-19–36amide or saline. In a subset of participants,
mean PP levels rose late after the GLP-1 injection
(Fig. 2B) due to excursions in a subset of participants.
Cardiovascular actions
Blood pressures are shown in Figure 3 (A–C). The
responses were very similar on all days, and there were
no significant differences between the groups. Heart rate
exhibited different time courses on the infusion days
(Fig. 4A). The GLP-1 injection resulted in an increase by
a maximum of about 14 beats per min peaking at
30 min, whereas the injection of exenatide elicited a simi-
lar, but slower rise (P > 0.05), still rising at 120 min.
Heart rate rose slightly after saline but remained stable
after GLP-19–36amide.
Stroke volume (Fig. 4B) decreased similarly (by around
15 mL) in all groups, but appeared to fall more after start
of GLP-1 with lower values at 15 and 30 min, but following
the other groups after that. Cardiac output (Fig. 4C)
decreased and by about 1 L/min during the 120 min per-
iod on the placebo day and a similar pattern was observed
after the GLP-1 metabolite, whereas cardiac output
remained stable on the exenatide day, and tended to rise
after the GLP-1 injection in parallel with the rise in heart
rate. GLP-1 briefly increased heart rate (at 15 and 30 min),
which was associated with a brief decrease in stroke vol-
ume, but nevertheless a small increase in cardiac output.
Blood flow
The results for RI are shown in Figure 5 (A–C) for all
three vessels. In the SMA, this parameter remained con-
stant and there were no changes in response to any of
the test compounds. The RI in the TC was more vari-
able, but again there were no clear changes after the
injections. The RA RI levels differed slightly on the dif-
ferent days and tended to decrease on all days. Also,
the TAMV (Fig. 6A–C) showed no consistent changes in
the SMA; a more variable pattern was observed in the
RA but without consistent changes in response to the
injections.
Discussion
The results regarding blood flow in the superior mesen-
teric, the celiac and the renal arteries in these studies are
highly surprising. As outlined in the introduction, there
were compelling reasons to believe that blood flow would
increase at least in the SMA. Thus, there are numerous
receptors for GLP-1 in the enteric nervous system, partic-
ularly in the enteric ganglia (Pyke et al. 2014), and
although the intestinal motor functions of the hormone
are probably predominantly inhibitory (Tolessa et al.
1998), GLP-1 is thought to have metabolic functions and
increases the growth of the gut (Simonsen et al. 2007). In
addition, administration of GLP-1 to surviving prepara-
tions of the ileum (Hansen and Holst 2002), as well as to
isolated mesenteric vessels (Ban et al. 2008), decreases the
vascular resistance (Ban et al. 2008), as was originally
demonstrated for pulmonary vessels (Richter et al. 1993).
The lack of effect is the more striking as the sister hor-
mone, GLP-2, which is released in parallel with GLP-1
from the intestinal L-cells (Orskov et al. 1986) and has
similar metabolic actions on the intestine (Drucker et al.
1996; Hartmann et al. 2000b) very markedly stimulates
SMA blood flow in healthy humans in an experimental
setting identical to the present one (Bremholm et al.
2009). Because the investigators, methods and equipment
were the same, we assume that we would have been able
to pick up a change in blood flow had there been one.
We obtained the plasma concentrations of the test com-
pounds that we had planned, that is, very significant and
rather long-lasting elevations (compared to iv injections)
in a meal-like pattern of both total GLP-1 and active
GLP-1 concentrations and of the metabolite as well. We
deliberately chose a dose of GLP-1 which would result in
higher than normal postprandial concentrations of both
the active hormone and the metabolite, because such con-
centrations may be seen in individuals with accelerated
gastric emptying after, e.g., gastric bypass surgery (Korner
et al. 2005). Thus, the values obtained are physiologically
relevant and at the same time sufficiently high to exclude
nondetection of effects because of too weak stimulation.
As expected, the injected GLP-1 was rapidly broken down
to the metabolite GLP-19–36amide, but the concentrations
of the intact peptide were elevated for a sufficiently long
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Figure 2. Glucose, insulin, C-peptide, and pancreatic polypeptide (PP). Symbol legends for the four experimental days; exenatide (squares),
GLP-1 (triangles), GLP-19–36amide (inverted triangles), and saline (circles). (A) Plasma glucose: Days were compared by a two-way ANOVA
(infusion (P = 0.0001), time (P = 0.0001), and infusion 9 time (P = 0.0001)). Post hoc test (Tukey) yielded significant differences; exenatide
versus saline/GLP-1 9–36NH2 ($), exenatide versus GLP-17–36amide (*), GLP-1 versus saline/GLP-19–36amide (#). (B) Plasma PP: Days were compared
by a two-way ANOVA (infusion (P < 0.0001), time (P = 0.012), infusion 9 time (P = 0.56)). Post hoc test (Tukey) yielded significant differences;
exenatide versus GLP-1 (&), GLP-1 versus saline (€). (C) Time courses for serum insulin. (D) Incremental AUCs (iAUCs) for insulin: iAUCs were
compared by a one-way ANOVA (P = 0.006), post hoc test (Tukey) yielded significant differences denoted by asterisk (*). (E) Time courses for
serum C-peptide. (F) Incremental AUCs for C-peptide: iAUCs were compared by a one-way ANOVA (P = 0.0001), post hoc test (Tukey) yielded
significant differences denoted by asterix (*). Data are means (SEM). Two-sided P < 0.05 were considered significant.
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Figure 3. Blood pressures. Symbol legends for the four
experimental days; exenatide (squares), GLP-1 (triangles), GLP-19–
36amide (inverted triangles), Saline (circles). (A) Systolic blood
pressure (Systolic BP): Days were compared by a two-way ANOVA
(infusion (P = 0.053), time (P < 0.0001), and infusion 9 time
(P = 0.93)). (B) Diastolic blood pressure (Diastolic BP): Days were
compared by a two-way ANOVA (infusion (P = 0.075), time
(P < 0.0001), and infusion 9 time (P = 0.99)). (C) Mean arterial
blood pressure (MAP): Days were compared by a two-way ANOVA
(infusion (P = 0.057), time (P < 0.0001), and infusion 9 time
(P = 0.92)). Data are means (SEM). Two-sided P < 0.05 were
considered significant.
Figure 4. Cardiac parameters. Symbol legends for the four
experimental days; exenatide (squares), GLP-1 (triangles), GLP-19–
36amide (inverted triangles), Saline (circles). (A) Heart rate: Days were
compared by a two-way ANOVA (injection (P = 0.0162), time
(P = 0.0038), and injection 9 time (P = 0.082)). Post hoc testing
(Tukey) yielded a significant difference, GLP-1 versus saline & GLP-
19–36amide (*). (B) Stroke volume: Days were compared by a two-
way ANOVA (injection (P = 0.51), time (P = 0.0050),
injection 9 time (P > 0.99)). (C) Cardiac output: Days were
compared by a two-way ANOVA (injection (P = 0.92), time
(P = 0.66), and injection 9 time (P > 0.99)). Data are means (SEM).
Two-sided P < 0.05 were considered significant.
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Figure 6. TAMV. Symbol legends for the four experimental days;
exenatide (squares), GLP-1 (triangles), GLP-19–36amide (inverted
triangles), saline (circles). (A) TAMV (superior mesenteric artery,
SMA): Days were compared by a two-way ANOVA (infusion
(P = 0.07), time (P = 0.36), infusion 9 time (P = 0.97)). (B) TAMV
(celiac trunk, TC): Days were compared by a two-way ANOVA
(infusion (P < 0.0001), time (P = 0.98), and infusion 9 time
(P > 0.99)). (C) TAMV (Renal artery, RA): Days were compared by a
two-way ANOVA (infusion (P = 0.0003), time (P = 0.99), and
infusion 9 time (P = 0.35)). Post hoc testing (Tukey) identified a
significant difference between exenatide and GLP-1 and GLP-19–
36amide (*). Data are means (SEM). Two-sided P < 0.05 were
considered significant. TAMV, Time averaged mean velocity.
Figure 5. Resistive indices. Symbol legends for the four
experimental days; exenatide (squares), GLP-1 (triangles), GLP-19–
36amide (inverted triangles), Saline (circles). (A) resistive index (RI)
(superior mesenteric artery, SMA): Days were compared by a two-
way ANOVA (infusion (P = 0.45), time (P = 0.85), and
infusion 9 time (P > 0.99)). (B) RI (celiac trunk, TC): Days were
compared by a two-way ANOVA (infusion (P = 0.14), time
(P = 0.95), and infusion 9 time (P > 0.99)). (C) RI (Renal artery,
RA): Days were compared by a two-way ANOVA (infusion
(P = 0.0044), time (P = 0.17), and infusion 9 time (P > 0.99)). Post
hoc testing (Tukey) did not yield any time points where curves
differed significantly. Data are means (SEM). Two-sided P < 0.05
were considered significant.
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period to elicit marked effects on insulin and C-peptide
concentrations, and also resulted in significant lowering
of blood glucose. Thus, both the injected native GLP-1
and the stable GLP-1 receptor agonist exenatide (a syn-
thetic form of exendin-4, a full GLP-1 receptor agonist
(Thorens et al. 1993) )had the expected metabolic effects
demonstrating that the experimental conditions for the
experiments were appropriate. In a subset of participants,
a marked rise in PP was observed, ostensibly elicited by
the drop in the glucose levels, rather than a direct stimu-
latory effect of GLP-1(Schwartz et al. 1978). This would
account for the timing of the PP increment and also illus-
trates a probable involvement of the autonomic nervous
system at this time point.
Exenatide was included in the study because we
wanted to investigate a stable GLP-1 receptor agonist,
which is widely used for therapeutic purposes (Klonoff
et al. 2008) and which does not give rise to the metabo-
lite, GLP-19–36amide, which might influence the results.
The metabolite was included for the same reason,
namely that it might have biological effects of its own.
Thus, the metabolite may act as a competitive (but less
potent) antagonist on the GLP-1 receptor (Knudsen and
Pridal 1996), which could conceal effects of the intact
hormone (Wettergren et al. 1998a); but, in addition, it
has been reported to have effects of its own, viz. lower-
ing of plasma glucose levels independently of insulin
secretion (Deacon et al. 2002; Meier et al. 2006), and
perhaps more importantly to have effects on both the
heart and on mesenteric vessels (relaxation) that appear
to be independent of the known GLP-1 receptor (Ban
et al. 2008). Neither of these effects could be demon-
strated in this study, however.
In agreement with several other studies, both GLP-1
and exenatide had effects on some of the cardiovascular
parameters investigated. The most conspicuous was the
increase in heart rate. The increase clearly followed the
plasma concentrations of the two peptides with a rapid
rise and decline after native GLP-1 and a steady rise
after exenatide. Currently, the mechanisms behind this
effect, which is also observed clinically (Sun et al. 2015),
are highly debated. However, the mechanisms behind
the effects observed chronically during therapy and
acutely as in the present study may not be the same. It
is currently unclear where the responsible receptor might
be located; using improved technology many of the pos-
itive findings regarding receptor localization in earlier
studies have been refuted (Ussher and Drucker 2014),
and the only (surviving) location in the heart of pri-
mates appeared to be in the sinoatrial node (Pyke et al.
2014), which could be consistent with a chronotropic
effects of GLP-1 directly on the heart. A similar location
could not be identified in rodents, but full-length
transcripts of the receptor were found in atrial tissue
(Ussher and Drucker 2014). Acute responses to native
GLP-1 with respect to heart rate in humans have been
inconsistent, with most studies showing negative effects
(Sivertsen et al. 2012). With the present mode of admin-
istration, however, a robust response was obtained which
could be helpful in further studies. However, there was
also a rather pronounced decrease in blood glucose,
which might cause increased central sympathetic out-
flow. Further investigations with clamping of blood glu-
cose levels would be required to sort this out. Notably,
the metabolite did not significantly affect heart rate. At
any rate, the increase in heart rate after GLP-1 was asso-
ciated with a rise in cardiac output, apparently
outweighing the decrease in stroke volume. This may
explain the tendency to higher blood pressures during
the GLP-1 infusion, presumably resulting from the effect
on heart rate. This is in contrast to observations during
chronic GLP-1 agonist therapy where a drop in blood
pressure is regularly observed (Sun et al. 2015). Again, a
good explanation for this has not been found, and
vasodilation has been proposed to explain this perhaps
in combination with natriuretic effects (Gutzwiller et al.
2004), but as documented in the present study, vasodila-
tion in the RA, the SMA, and the TC is unlikely to
explain the lower blood pressure, which may rather
reflect capillary recruitment in muscles and fat tissue
(Sjøberg et al. 2014).
GLP-1 may have pronounced renal effects including
increased natriuresis (Gutzwiller et al. 2006), but the cou-
pling to renal blood flow is uncertain (Asmar et al. 2015),
and contrasting results have been reported depending on
the experimental setting (Skov et al. 2013; Jensen et al.
2015). We did not measure diuresis in these studies, but
on the other hand did not find any changes in renal
blood flow in agreement with previous studies in healthy
humans (Asmar et al. 2015).
In very recent studies in humans, SMA blood flow was
measured during meal intake or intraduodenal glucose
instillation (Trahair et al. 2014, 2015). In the first case,
SMA blood flow was lowered, whereas in the latter, it
increased. The decrease was interpreted to reflect inhibi-
tory effects of GLP-1 on gastric emptying (Wettergren
et al. 1993) (which is probably due to inhibition of cen-
tral vagal outflow (Wettergren et al. 1998b) which could
also influence blood flow), whereas the increase during
intraduodenal glucose could have many explanations
given the many metabolic reactions resulting from
intraduodenal glucose + GLP-1.
In conclusion, GLP-1 has metabolic and cardiovascular
effects in humans but, surprisingly and unlike its sister
peptide GLP-2, it does not seem to influence intestinal
blood flow.
ª 2017 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
The Physiological Society and the American Physiological Society.
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